Acadia
acadia.xyz
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
K5 Global
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
K5 Global Similar startupsby what they do, their industry and backers
AI-powered Coverage Intelligence for specialty practices. Manta Health protects revenue upstream by automating eligibility, authorizations…
AI-powered patient payment software built for specialty practices. Cut days-to-pay from 60 to 15, automate outreach, and get patients paid…
Integrate payments, collections, and financial services in one place at the speed and scale your business demands.
You built your specialty practice to care for patients.. Plena handles the complex workflows your staff shouldn't have to do. All running…
Motivity delivers ABA practice management, electronic data collection, scheduling, billing, and RCM tools. All in one platform designed for…
The only platform to automate payment collection end-to-end. Eliminate manual work, reduce late payments and accelerate cash flow.
Overview
RCM Automation Agents for Specialty Practices. Our AI Agents power faster patient and insurance payment collection by automating key workflows.
News
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop
Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expecta
Read more
Report
Acadia Reports Phase 2 Data for Alzheimer's Psychosis
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Read more
Report
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer's data
Novo's latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
Read more
Report
Acadia slides on Phase 2 miss in Alzheimer's psychosis but keeps moving asset forward
While Acadia Pharmaceuticals' candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer's disease as well as Lewy body dementia.
Read more
Report
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP)
SAN DIEGO, September 24, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations
Read more
Report
Report
Show more news